Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSKN033 + Platinum-Based Chemotherapy +/- Bevacizumab in Advanced Cervical Cancer
NCT07497074Phase 2Not yet recruiting
- Sponsor
- Alphamab Oncology
- Start
- Apr 2026
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of JSKN033 in Cervical Cancer (CC) (3 cohorts), sponsored by Alphamab Oncology. Primary endpoints: Treatment-Emergent Adverse Events at 21 days, Treatment-Related Adverse Events at 21 days and 2 more. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
JSKN033
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT07497074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07497074.